Analysts See $-0.08 EPS for Idera Pharmaceuticals, Inc. (IDRA)

February 20, 2018 - By Marie Mckinney

 Analysts See $ 0.08 EPS for Idera Pharmaceuticals, Inc. (IDRA)
Investors sentiment decreased to 1.36 in 2017 Q3. Its down 0.10, from 1.46 in 2017Q2. It fall, as 5 investors sold Idera Pharmaceuticals, Inc. shares while 20 reduced holdings. 11 funds opened positions while 23 raised stakes. 46.97 million shares or 1.60% more from 46.23 million shares in 2017Q2 were reported.
Guggenheim Lc invested 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Palo Alto Investors Limited Liability reported 0.06% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Jpmorgan Chase Com reported 3.36M shares. Natixis invested in 0.07% or 3.16M shares. Moreover, Millennium Management Llc has 0.01% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Moreover, California Pub Employees Retirement Sys has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Nationwide Fund Advsrs invested in 61,173 shares. Creative Planning has invested 0% of its portfolio in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Schwab Charles Invest Mngmt Inc reported 322,929 shares. Morgan Stanley holds 155,772 shares or 0% of its portfolio. 120,231 are held by Rhumbline Advisers. Gru One Trading Lp accumulated 56,712 shares or 0% of the stock. State Street Corporation stated it has 1.88M shares or 0% of all its holdings. Royal Bank & Trust Of Canada invested in 0% or 21,719 shares. Mycio Wealth Partners Limited Liability Company holds 246,527 shares.

Since October 26, 2017, it had 1 insider buy, and 2 sales for $7.00 million activity. Shares for $12.00M were bought by BAKER BROS. ADVISORS LP.

Analysts expect Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) to report $-0.08 EPS on March, 21.They anticipate $0.09 EPS change or 900.00 % from last quarter’s $0.01 EPS. After having $-0.10 EPS previously, Idera Pharmaceuticals, Inc.’s analysts see -20.00 % EPS growth. The stock increased 1.05% or $0.02 during the last trading session, reaching $1.93. About 1.32 million shares traded. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has risen 21.13% since February 20, 2017 and is uptrending. It has outperformed by 4.43% the S&P500.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ratings Coverage

Among 4 analysts covering Idera Pharma (NASDAQ:IDRA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharma had 7 analyst reports since January 6, 2016 according to SRatingsIntel. The stock of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) earned “Outperform” rating by Wedbush on Wednesday, February 1. The rating was maintained by Piper Jaffray with “Buy” on Thursday, November 9. The firm has “Outperform” rating given on Wednesday, January 6 by Wedbush. H.C. Wainwright maintained Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) rating on Thursday, November 16. H.C. Wainwright has “Buy” rating and $4.0 target. The rating was maintained by Piper Jaffray on Monday, September 11 with “Buy”.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company has market cap of $377.58 million. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense technology. It currently has negative earnings. The company's drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis.

More notable recent Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) news were published by: Fool.com which released: “Why II-VI, Sanmina, and Idera Pharmaceuticals Slumped Today” on January 22, 2018, also Prnewswire.com with their article: “RM LAW Announces Investigation of Idera Pharmaceuticals, Inc.” published on January 30, 2018, Globenewswire.com published: “BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming …” on February 19, 2018. More interesting news about Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) were released by: Globenewswire.com and their article: “BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine …” published on January 22, 2018 as well as Businesswire.com‘s news article titled: “Bragar Eagel & Squire, PC is Investigating the Board of Directors of Idera …” with publication date: January 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.